Substituted Amide Btk Inhibitors for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis, are limited in effectively targeting Bruton's Tyrosine Kinase (Btk) activity, which is crucial for B-cell activation and inflammatory responses, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of specific substituted amides and related compounds that act as pharmacophores to inhibit Btk activity, including pharmaceutically acceptable salts, solvates, and complexes, which can be administered to treat diseases responsive to Btk inhibition, thereby reducing B-cell activation and inflammatory cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to target Btk activity, then B-cell activation can be inhibited, but therapeutic outcomes remain suboptimal
Solution Approach 1:
The patent modifies the chemical structure of Btk inhibitors by changing parameters such as introducing specific substituents (e.g., fluorine atoms at positions 2 and 6 of the pyridine ring), adjusting molecular weight, and optimizing pharmacophore configurations. These parameter changes result in compounds with enhanced binding affinity and selective inhibition of Btk activity, thereby improving therapeutic outcomes.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional moieties within a single inhibitor compound. Examples include molecules that integrate pyridine rings, amide groups, and various substituent groups (e.g., carboxylic acid, ester, or amide groups) to create multi-functional inhibitors that simultaneously target Btk activity while reducing off-target effects.
2Reliability
If Btk inhibitors are administered to treat autoimmune diseases, then B-cell activation is reduced, but side effects may occur
Solution Approach 1:
The patent introduces local modifications at specific positions within the molecular structure to enhance selectivity. For example, placing fluorine atoms at specific positions (2 and 6) of the pyridine ring creates local electronic effects that improve binding specificity to Btk while minimizing interactions with other kinases. This localized optimization reduces off-target side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent utilizes structure-activity relationship (SAR) data to identify and synthesize analogs and derivatives of lead compounds. By systematically copying and modifying successful molecular features while removing problematic elements, the patent develops a series of optimized inhibitors that maintain efficacy while reducing toxicity. Examples include creating analogs with modified side chains or ring structures that preserve binding affinity but improve pharmacokinetic properties.
Data Source
AI summary
At least one chemical entity chosen from compounds of Formula 2and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein.Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described.Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.